中怡國際(02341.HK)已書面要求上市委員會覆核除牌決定
中怡國際(02341.HK)公布,於10月27日接獲聯交所發出的函件,聯交所上市委員會已決定拒絕公司延長復牌期限的要求,以及根據上市規則第6.01A條取消公司的上市地位。
函件指出,除非公司申請上市覆核委員會覆核,否則公司股份的最後上市日期將為本周五(10日),且公司股份將自下周一(13日)上午九時正起取消上市地位。
公司於周一(6日)已根據上市規則第2B章向聯交所提交書面要求,將決定及駁回要求轉介上市覆核委員會進行上市覆核委員會覆核。
應公司要求,公司股份已於去年4月4日起於聯交所暫停買賣,並將繼續暫停買賣,直至另行通知。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.